Overview

Rosuvastatin (Crestor) in Friedreich Ataxia

Status:
Completed

Trial end date:
2017-08-04

Target enrollment:

Participant gender:

Summary

This study is an exploratory open-label clinical trial of Rosuvastatin in patients with Friedreich ataxia (FRDA). This is an outpatient trial with the goal of enrolling 10 evaluable adults with genetically confirmed FRDA who are between the ages of 18-65. Subjects will receive 10mg of oral Rosuvastatin daily for three months.

Phase:

Early Phase 1

Details

Lead Sponsor:

Children's Hospital of Philadelphia

Collaborator:

Friedreich's Ataxia Research Alliance

Treatments:

Rosuvastatin Calcium